LEVI-04 is under clinical development by Levicept and currently in Phase II for Osteoarthritis Pain. According to GlobalData, Phase II drugs for Osteoarthritis Pain have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LEVI-04’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LEVI-04 overview

LEVI-04 is under development for the treatment of osteoarthritis pain and chronic pain. It is administered through intravenous infusion. The drug candidate is a novel first in class fusion protein (p75NTR-Fc) in which p75 neurotrophin receptor (p75 NTR) fused with an Fc fragment that binds nerve growth factor receptor. It acts by targeting low-affinity nerve growth factor receptor NGFR.

For a complete picture of LEVI-04’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.